Glycogen Storage Disorders

Last updated by Peer reviewed by Dr Krishna Vakharia
Last updated Meets Patient’s editorial guidelines

Added to Saved items
This article is for Medical Professionals

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Glycogen Storage Disorders article more useful, or one of our other health articles.

Read COVID-19 guidance from NICE

Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.

Glycogen is a branched-chain polymer of glucose and serves as a dynamic but limited reservoir of glucose, mainly in liver, skeletal muscle, heart, and sometimes the central nervous system and the kidneys.[1] There are a number of different enzymes involved in glycogen synthesis, utilisation and breakdown within the body.

Glycogen storage disorders (GSDs) are a group of inherited inborn errors of metabolism caused by deficiency or dysfunction of these enzymes.[2]

  • Glycogen synthesis errors result in decreased production of normal glycogen ± deposition of abnormally branched glycogen chains.
  • Degradation errors block formation of glucose from glycogen, leading to hypoglycaemia and pathological accumulation of glycogen in the tissues.

These metabolic errors can be confined to just liver and muscle but some cause more generalised pathology and affect tissues such as the kidney, heart and bowel. The GSD classification is based on the enzyme deficiency and the affected tissue.[3]

  • The overall GSD incidence is estimated at 1 case per 20,000-43,000 live births.[4]
  • Type I is the most common (25% of all GSDs).
  • Suspect in infants and children with growth restriction, hypoglycaemia and hepatomegaly.
  • In juveniles and adults, GSD tends to present with fatigue and weakness on exercising, and either myositis or myopathy.
  • Autosomal recessive (I, II, III, IV, V, VI, VII, some IX, Xl, 0). Both parents are carriers. The chance of a sibling being affected is 1 in 4.
  • X-linked (some IX).

See the separate article on Von Gierke's Glycogen Storage Disease.

  • Affected enzymes: glucose-6-phosphatase translocase deficiencies.
  • Clinical features:
    • As in Von Gierke's disease with variable clinical expression but also immunosuppression (altered neutrophil functions) leading to infection. Pneumonia and oral infections are often seen.
    • May suffer from severe diarrhoea due to granulomatous infiltration of colonic mucosa.
  • Treatment: as in Von Gierke's disease but avoid infection. May need prophylactic antibiotics.
  • Affected enzymes: caused by mutations in the gene coding for acid alpha-glucosidase (GAA), the enzyme that breaks down glycogen in lysosomes. Once in the lysosome, glycogen can escape following complete degradation by GAA in the form of glucose. A deficiency of the enzyme leads to lysosomal accumulation of glycogen in multiple tissues, but cardiac and skeletal muscles are most severely affected.
  • Clinical features: Pompe's disease affects people of all ages with varying degrees of severity. Two broad types are recognised based on the onset of symptoms and the presence or absence of cardiomyopathy:
    • The most severe form, referred to as classic infantile onset Pompe's disease is characterised by the age of onset at up to 12 months, rapidly progressive hypertrophic cardiomyopathy, left ventricular outflow obstruction, hypotonia and muscle weakness, respiratory distress, and progressive loss of independent ventilation. Breathing difficulties, feeding problems, and macroglossia are common. Motor development is significantly delayed, and major developmental milestones are often not achieved. Only a small percentage of untreated patients survive beyond 1 year of age and the main cause of death is cardiac and respiratory failure.
    • Less devastating late-onset Pompe disease manifests any time after 12 months of age, usually without significant cardiac involvement. Late-onset patients commonly present with the symptoms of proximal limb-girdle myopathy. The progression of the symptoms is relatively slow but ultimately leads to profound muscle weakness and wasting, wheelchair dependency, and respiratory failure due to the involvement of the diaphragm. Additional symptoms include dysarthria and dysphagia, osteoporosis, scoliosis, sleep apnoea, small fibre neuropathy, hearing loss, impaired gastric function, urinary tract and anal sphincter involvement, and pain and fatigue, as well as a risk of cardiac arrhythmia and cerebral and intracranial aneurysms.
  • Treatment: the mainstay of treatment is now enzyme replacement therapy.

Synonyms: Forbes' disease, Forbes-Cori disease

  • Affected enzyme: glycogen debranching enzyme. Deposition of abnormal glycogen structure.
  • Affected tissues: liver and muscle.
  • Clinical features:
    • Seizures in infancy, hypoglycaemia, poor growth, hepatomegaly, moderate progressive myopathy.
    • Symptoms can regress with age.
    • A few cases of liver cirrhosis and hepatocellular carcinoma have been reported.[8]
  • Specific biochemical features: hyperlipidaemia.
  • Treatment: as with type I; also protein supplements for muscle disorder.
  • Affected enzyme: transglucosidase (glycogen branching enzyme). Abnormally structured glycogen forms.
  • Affected tissues: many, including liver. Rare variant affects peripheral nerves.
  • Clinical features:
    • Hepatomegaly, failure to thrive, cirrhosis, splenomegaly, jaundice, hypotonia, waddling gait, lumbar lordosis.
  • Treatment: adherence to a dietary regimen may reduce liver size, prevent hypoglycaemia and improve growth and development. Management of organ failure as required.
  • Complications: include hepatocellular carcinoma, liver failure, heart failure, nerve dysfunction and ventricular arrhythmia.
  • Prognosis: mostly death by age 4, due to cirrhosis and portal hypertension.

See the separate article on McArdle's Glycogen Storage Disease.

In the past, types VIII and X were considered distinct conditions but they are now classified with type VI.

  • Affected enzyme: liver phosphorylase.
  • Affected tissues: liver; there is a rare cardiac form.
  • Clinical features:
    • The most common variant is X-linked and therefore usually affects only males.
    • Hepatomegaly, hypoglycaemia, growth restriction, hyperlipidaemia.
  • Specific biochemical features: mild ketosis, hyperlipidaemia.
  • Treatment: cardiac transplantation for the rare cardiac form. May need frequent feeding to avoid hypoglycaemia.
  • Prognosis: usually, a normal lifespan.

See the separate article on Phosphofructokinase Deficiency.

  • Affected enzyme: hepatic phosphorylase kinase.[12]
  • Affected tissues: liver.
  • Clinical features:: divided into types IXa and IXb; both are relatively benign. Clinical symptoms in IXa include hepatomegaly, growth restriction, hyperlipidaemia and fasting ketosis. The clinical and biochemical abnormalities gradually disappear by adulthood.[12]
  • Affected enzyme: glucose transporter 2 (GLUT2).
  • Clinical features: hepatomegaly, glucose and galactose intolerance, fasting hypoglycaemia, proximal tubular nephropathy and severe short stature. Symptoms persist into adulthood.
  • Treatment: there is no specific therapy available. Symptomatic treatment to provide stable glucose homeostasis and compensate for renal losses of various solutes.

GSD type 0 is a rare form, representing less than 1% of all cases.

  • Affected enzyme: hepatic glycogen synthase.
  • Affected tissues: liver.
  • Clinical features: fasting, ketotic hypoglycaemia when ceasing night-time feeds in infants or between meals in older children. Seizures can occur. Postprandial hyperglycaemia. Fatigue and muscle cramps after exertion. Mild growth restriction in some cases.
  • Specific biochemical features:
    • Hypoglycaemia, ketosis, raised fasting lactate.
    • Glycosuria and ketonuria occur after breakfast and therefore may be confused with diabetes mellitus.
  • Treatment: adequate diet and avoidance of fasting hypoglycaemia.
  • Prognosis: normal growth and intellectual development if diagnosed early and episodes of hypoglycaemia are prevented.
  • Blood tests:
    • Blood glucose: hypoglycaemia is likely.
    • LFTs: monitoring for hepatic failure.
    • Anion gap calculation: if glucose is low, this may indicate lactic acidaemia.
    • Urate: there may be high urate levels and even associated gout.
    • Renal function tests.
    • Creatine kinase.
    • FBC: there may (rarely) be anaemia, neutropenia.
    • Coagulation studies: increased bleeding tendency may occur.
    • Lipids: hyperlipidaemia occurs in some types of GSD.
  • Urine tests: myoglobinuria after exercise - found in 50% of people with McArdle's disease.
  • Imaging:
    • Abdominal ultrasound scan: hepatomegaly.
    • Echocardiography: cardiac involvement in certain types of GSD.
  • Biopsy of liver, muscle or other tissues gives definitive diagnosis. However, biopsy has now largely been replaced by genetic testing.
  • Direct biochemical assay of tissues for glycogen and fat content and enzyme analysis.
  • Other tests:
    • Glucagon stimulation test: in GSD there is not the normal rise in blood glucose.
    • DNA analysis from peripheral lymphocytes for McArdle's disease.

Prenatal diagnosis

  • Genetic counselling.
  • Referral to a geneticist for possible prenatal investigation and diagnosis.

Are you protected against flu?

See if you are eligible for a free NHS flu jab today.

Check now

Further reading and references

  1. Hicks J, Wartchow E, Mierau G; Glycogen storage diseases: a brief review and update on clinical features, genetic abnormalities, pathologic features, and treatment. Ultrastruct Pathol. 2011 Oct35(5):183-96. doi: 10.3109/01913123.2011.601404.

  2. DiMauro S, Spiegel R; Progress and problems in muscle glycogenoses. Acta Myol. 2011 Oct30(2):96-102.

  3. Oldfors A, DiMauro S; New insights in the field of muscle glycogenoses. Curr Opin Neurol. 2013 Oct26(5):544-53. doi: 10.1097/WCO.0b013e328364dbdc.

  4. Ozen H; Glycogen storage diseases: New perspectives. World J Gastroenterol. 2007 May 1413(18):2541-53.

  5. Glycogen Storage Disease Ib, GSD1B; Online Mendelian Inheritance in Man (OMIM)

  6. Kohler L, Puertollano R, Raben N; Pompe Disease: From Basic Science to Therapy. Neurotherapeutics. 2018 Oct15(4):928-942. doi: 10.1007/s13311-018-0655-y.

  7. Glycogen Storage Disease III, GSD3; Online Mendelian Inheritance in Man (OMIM)

  8. Demo E, Frush D, Gottfried M, et al; Glycogen storage disease type III-hepatocellular carcinoma a long-term complication? J Hepatol. 2007 Mar46(3):492-8. Epub 2006 Nov 9.

  9. Glycogen Storage Disease IV, GSD4; Online Mendelian Inheritance in Man (OMIM)

  10. Glycogen Storage Disease VI, GSD6; Online Mendelian Inheritance in Man (OMIM)

  11. Tsilianidis LA, Fiske LM, Siegel S, et al; Aggressive therapy improves cirrhosis in glycogen storage disease type IX. Mol Genet Metab. 2013 Jun109(2):179-82. doi: 10.1016/j.ymgme.2013.03.009. Epub 2013 Mar 21.

  12. Glycogen storage disease IX; Online Mendelian Inheritance in Man (OMIM)

  13. Glycogen Storage Disease XI, Fanconi-Bickel syndrome; Online Mendelian Inheritance in Man (OMIM

  14. Glycogen Storage Disease 0, Liver; Online Mendelian Inheritance in Man (OMIM)

  15. Glycogen Storage Disease 0, Muscle; Online Mendelian Inheritance in Man (OMIM)

  16. Berardo A, DiMauro S, Hirano M; A diagnostic algorithm for metabolic myopathies. Curr Neurol Neurosci Rep. 2010 Mar10(2):118-26. doi: 10.1007/s11910-010-0096-4.